-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Initiates Coverage On BridgeBio Pharma with Outperform Rating, Announces Price Target of $100

Benzinga·04/09/2026 15:20:50
Listen to the news
RBC Capital analyst Luca Issi initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Outperform rating and announces Price Target of $100.